Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Hoechst Marion Roussel

Executive Summary

Hoechst Marion Roussel: Requests FTC approval to license generic dicyclomine for treatment of irritable bowel syndrome to DuPont Merck subsidiary Endo Labs to fulfill the consent decree Marion Merrell Dow signed with FTC for final approval of its Rugby acquisition in May 1994, FTC announces Oct. 6. Under the consent decree, MMD agreed that within 12 months of the final date of the consent decree it would license dicyclomine formulation and product technology to a third party and contract manufacture of dicyclomine with a third party until it gains FDA approval for its own product ("The Pink Sheet" June 27, 1994, T&G-12). Hoechst's request will be subject to public comment until Nov. 6...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel